◀ Back to MMP9

HBEGF — MMP9

Pathways - manually collected, often from reviews:

• NCI Pathway Database Plasma membrane estrogen receptor signaling: MMP9 (MMP9) → HB-EGF (HBEGF) (modification, activates) Razandi et al., J Biol Chem 2003*
  Evidence: mutant phenotype
• NCI Pathway Database LPA receptor mediated events: MMP9 (MMP9) → HB-EGF (HBEGF) (modification, activates) Zhao et al., J Biol Chem 2006*
  Evidence: mutant phenotype, assay
• NCI Pathway Database LPA receptor mediated events: MMP9 (MMP9) → HB-EGF (63-148) (HBEGF) (modification, activates) Zhao et al., J Biol Chem 2006*
  Evidence: mutant phenotype, assay

Text-mined interactions from Literome

Shah et al., Mol Endocrinol 2004 : These data demonstrate that the individual actions of Ang II on EGF-R transactivation in specific cell types are related to differential involvement of MMP dependent HB-EGF release
Zhou et al., Am J Physiol Heart Circ Physiol 2007 : Inhibition of heparin binding EGF-like growth factor ( HB-EGF ) release by CRM-197 and inhibition of matrix metalloproteinases ( MMP ) by GM-6001 abolished PAF induced MAP kinase activation and cell proliferation
Ogunwobi et al., Br J Biomed Sci 2008 (Adenocarcinoma...) : Leptin increased extracellular release of HB-EGF and TGFalpha and this was blocked by matrix metalloproteinase ( MMP ) inhibitors